Adlai Nortye (bonus event - Catalysts)Adlai Nortye was supposed to be a bridging trial (boring dose escalation) bla bla bla nerdy stuff.
Now there are partial responses... Plus we are waiting for more updated data!!! This is the buzz here. A surprise bonus event prior to bracelet-1 data.
This will enflamme expectation! Program Number: P3-07-04
Session Title: Poster Session 3
Session Date: December 7, 2022
Session Time: 5 p.m. CT
Results published in the SABCS abstract indicate that pelareorep in combination with paclitaxel was safe, well tolerated, and showed anti-tumor activity in Adlai Nortye's single-arm bridging clinical trial in Chinese patients with advanced or metastatic HR+/HER2- breast cancer. As of the abstract's data cut-off date (June 2, 2022), ten patients had been treated in the trial, with four achieving a partial response (two confirmed, two unconfirmed) and five showing stable disease (SD). Eight of the nine patients achieving a partial response (PR) or SD remained on study and continued to receive treatment as of the cut-off date. Updated and additional data from the trial will be presented in the poster corresponding to the abstract in accordance with the SABCS embargo policies.
The bridging trial is designed to accelerate Adlai Nortye's development of pelareorep in China by allowing future regulatory submissions to include data from Oncolytics' North American metastatic breast cancer trials, IND-213 and BRACELET-1.